相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial
Yajing Zhang et al.
LEUKEMIA (2022)
Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity
Nina Dumauthioz et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy
Pedro Velica et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Navigating CAR-T cells through the solid-tumour microenvironment
Andrew J. Hou et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
Joseph H. Choe et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Immune checkpoint signaling and cancer immunotherapy
Xing He et al.
CELL RESEARCH (2020)
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah et al.
NATURE COMMUNICATIONS (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong et al.
CANCER CELL (2020)
Engineering CAR T Cells to Target the HIV Reservoir
Wenli Mu et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Xian Zhang et al.
BLOOD ADVANCES (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy
Luana Guerra et al.
CELL REPORTS (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
CD19-CAR-T Cells Bearing a KIR/PD-1-Based Inhibitory CAR Eradicate CD19+HLA-C1- Malignant B Cells While Sparing CD19+HLA-C1+ Healthy B Cells
Lei Tao et al.
CANCERS (2020)
Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity
Jun-Kyu Byun et al.
MOLECULAR CELL (2020)
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
The clinical potential of gene editing as a tool to engineer cell-based therapeutics
Candice Ashmore-Harris et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
Rakesh Awasthi et al.
BLOOD ADVANCES (2020)
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
Shivani Srivastava et al.
CANCER CELL (2019)
Targeting Tumor Microenvironment for Cancer Therapy
Catarina Roma-Rodrigues et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Matthew R. Collinson-Pautz et al.
LEUKEMIA (2019)
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
Boris Gorovits et al.
BIODRUGS (2019)
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Robert Berahovich et al.
CANCERS (2019)
Modulation of chimeric antigen receptor surface expression by a small molecule switch
Alexandre Juillerat et al.
BMC BIOTECHNOLOGY (2019)
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Hao Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
Manuel Wiesinger et al.
CANCERS (2019)
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Robert D. Leone et al.
SCIENCE (2019)
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Jennifer N. Brudno et al.
BLOOD REVIEWS (2019)
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
Felicitas Rataj et al.
BRITISH JOURNAL OF CANCER (2019)
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Maura C. O'Leary et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
Najat Bouchkouj et al.
CLINICAL CANCER RESEARCH (2019)
Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Dwivedi Alka et al.
FRONTIERS IN IMMUNOLOGY (2019)
Metabolic Pathways Involved in Regulatory T Cell Functionality
Rosalie W. M. Kempkes et al.
FRONTIERS IN IMMUNOLOGY (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies
Maksim Mamonkin et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
Joana M. Murad et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Nanobody Based Dual Specific CARs
Stijn De Munter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients
Katherine T. Marcucci et al.
MOLECULAR THERAPY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zenan L. Chang et al.
NATURE CHEMICAL BIOLOGY (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Engineering Axl specific CAR and SynNotch receptor for cancer therapy
Jang Hwan Cho et al.
SCIENTIFIC REPORTS (2018)
Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
Monica Casucci et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Programming CAR-T cells to kill cancer
Louai Labanieh et al.
NATURE BIOMEDICAL ENGINEERING (2018)
PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti-PD-1 Therapy
Partha S. Chowdhury et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy
Charlotte M. Mousset et al.
ONCOIMMUNOLOGY (2018)
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Priyamvada Jayaprakash et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
TGF-β-responsive CAR-T cells promote anti-tumor immune function
Andrew J. Hou et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2018)
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma
Hui Yu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Xiaojuan Liu et al.
CELL RESEARCH (2017)
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
Kai-chao Feng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Leah Alabanza et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
Thomas Shum et al.
CANCER DISCOVERY (2017)
A versatile system for rapid multiplex genome-edited CAR T cell generation
Jiangtao Ren et al.
ONCOTARGET (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2017)
Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor Function
Yael Gropper et al.
CELL REPORTS (2017)
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Eunice Yuen-Ting Lau et al.
STEM CELLS INTERNATIONAL (2017)
A TCR-based Chimeric Antigen Receptor
Even Waiseng et al.
SCIENTIFIC REPORTS (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
Mammalian synthetic biology in the age of genome editing and personalized medicine
Patrick Ho et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2017)
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
Tanja Kaartinen et al.
CYTOTHERAPY (2017)
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Juliana Benito et al.
CLINICAL CANCER RESEARCH (2016)
Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery
Jianbin Wang et al.
NUCLEIC ACIDS RESEARCH (2016)
Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Nicholas Hubbard et al.
BLOOD (2016)
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2016)
Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche
David Clever et al.
CELL (2016)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Roger Geiger et al.
CELL (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Emerging concepts of T cell metabolism as a target of immunotherapy
Chih-Hao Chang et al.
NATURE IMMUNOLOGY (2016)
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Christoph T. Ellebrecht et al.
SCIENCE (2016)
TCR-engineered T cells to treat tumors: Seeing but not touching?
Reno Debets et al.
SEMINARS IN IMMUNOLOGY (2016)
A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
Reona Sakemura et al.
CANCER IMMUNOLOGY RESEARCH (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ping-Chih Ho et al.
CELL (2015)
The Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo
Julianna Blagih et al.
IMMUNITY (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template
Blythe D. Sather et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Efficient Gene Editing in Primary Human T Cells
Yvonne Y. Chen
TRENDS IN IMMUNOLOGY (2015)
Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Joseph G. Crompton et al.
CANCER RESEARCH (2015)
Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy
Mohamed L. Salem et al.
CYTOTECHNOLOGY (2015)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Ko Kudo et al.
CANCER RESEARCH (2014)
The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection
Matthew M. Staron et al.
IMMUNITY (2014)
Molecular mechanisms of retroviral integration site selection
Mamuka Kvaratskhelia et al.
NUCLEIC ACIDS RESEARCH (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Nicoletta Cieri et al.
BLOOD (2013)
The pre-metastatic niche: finding common ground
Jaclyn Sceneay et al.
CANCER AND METASTASIS REVIEWS (2013)
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
Michael Hudecek et al.
CLINICAL CANCER RESEARCH (2013)
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Madhusudhanan Sukumar et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
Andrew L. Doedens et al.
NATURE IMMUNOLOGY (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
Markus Chmielewski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Hypoxia-inducible factors and their roles in energy metabolism
Nobuhito Goda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
Alicia S. Chung et al.
JOURNAL OF PATHOLOGY (2012)
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy
Jon G. Quatromoni et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T-Cell Activation under Hypoxic Conditions Enhances IFN-gamma Secretion
Jessica Roman et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2010)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3ζ Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex
John S. Bridgeman et al.
JOURNAL OF IMMUNOLOGY (2010)
The VHL Tumor Suppressor: Master Regulator of HIF
Volker H. Haase
CURRENT PHARMACEUTICAL DESIGN (2009)
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
Christian S. Hinrichs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Biology of HIF-1 alpha
A. Weidemann et al.
CELL DEATH AND DIFFERENTIATION (2008)
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Salima Hacein-Bey-Abina et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Glucose uptake is limiting in T cell activation and requires CD28-mediated akt-dependent and independent pathways
Sarah R. Jacobs et al.
JOURNAL OF IMMUNOLOGY (2008)
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection
Matthias T. Stephan et al.
NATURE MEDICINE (2007)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
RN Kaplan et al.
NATURE (2005)
The role of extracellular spacer regions in the optimal design of chimeric immune receptors - Evaluation of four different scFvs and antigens
RD Guest et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
IDO expression by dendritic cells: Tolerance and tryptophan catabolism
AL Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2004)
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors
NM Haynes et al.
BLOOD (2002)
FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor
D Lando et al.
GENES & DEVELOPMENT (2002)
Transforming growth factor-beta in T-cell biology
L Gorelik et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions
CC Caldwell et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
